Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
Oncol Lett ; 24(2): 281, 2022 Aug.
Article de Anglais | MEDLINE | ID: mdl-35814830

RÉSUMÉ

Long non-coding RNAs (lncRNAs) are important biological factors that contribute to the initiation and progression of different types of cancer, including gastric, bladder and colorectal cancer. Small nucleolar RNA host gene 3 (SNHG3) has been implicated in prostate cancer (PCa) progression. However, the expression pattern and function of SNHG3 in PCa remain unclear, impeding the development of novel treatment strategies for this cancer. The present study aimed to investigate a combination of molecular and biochemical approaches to determine the role of SNHG3 in patients at different stages of disease, and elucidate the pathway by which SNHG3 affects PCa progression. A Cell Counting Kit-8 assay was used to assess cell proliferation. Transwell assays were used to analyze cell migration and invasion. Reverse transcription-quantitative PCR and western blotting were used to evaluate the expression levels of RNAs and proteins, respectively. The results demonstrated that SNHG3 expression was upregulated in PCa tissues downloaded from The Cancer Genome Atlas database, which was associated with poor prognosis. Furthermore, cell proliferation, migration and invasion were significantly inhibited following SNHG3 knockdown in vitro, the effects of which were reversed following overexpression of SNHG3 in PCa cells. Bioinformatic analysis revealed that microRNA (miRNA/miR)-1827 was a downstream target of SNHG3. The direct interaction between SNHG3 and miR-1827 was validated via the dual-luciferase reporter and RNA immunoprecipitation assays. Pearson's correlation analysis demonstrated that SNHG3 expression was negatively correlated with miR-1827 expression at different stages of PCa. Furthermore, rescue assays indicated that cotransfection with small interfering-SNHG3 and miR-1827 inhibitor reversed the effects of SNHG3 knockdown on cell proliferation, migration and invasion. In addition, SNHG3 knockdown in vivo suppressed tumor growth. Notably, lncRNA SNHG3 promoted PCa progression through miR-1827 via the Wnt/AKT/mTOR pathway. Taken together, the results of the present study suggest that SNHG3 promotes PCa progression by sponging miR-1827, indicating that SNHG3 may be a promising diagnostic and therapeutic target of PCa.

2.
PLoS One ; 13(8): e0201515, 2018.
Article de Anglais | MEDLINE | ID: mdl-30071061

RÉSUMÉ

OBJECTIVES: To develop and validate an individualized nomogram to predict probability of patients with ureteral calculi developing into urosepsis. METHODS: The clinical data of 747 patients with ureteral calculi who were admitted from June 2013 to December 2015 in Affiliated Nanhai Hospital of Southern Medical University were selected and included in the development group, while 317 ureteral calculi patients who were admitted from January 2016 to December 2016 were included in the validation group. The independent risk factors of ureteral calculi associated with urosepsis were screened using univariate and multivariate logistic regression analyses. The corresponding nomogram prediction model was drawn according to the regression coefficients. The area under the receiver operating characteristic curves and the GiViTI calibration belts were used to estimate the discrimination and calibration of the prediction model, respectively. RESULTS: Multivariate logistic regression analysis showed that the five risk factors of gender, mean computed tomography(CT) attenuation value of hydronephrosis, functional solitary kidney, urine white blood cell(WBC) count and urine nitrite were independent risk factors of ureteral calculi associated with urosepsis. The areas under the receiver operating characteristic curve of the development group and validation group were 0.913 and 0.874 respectively, suggesting that the new prediction model had good discrimination capacity. P-values of the GiViTI calibration test of the two groups were 0.247 and 0.176 respectively, and the 95% CIs of GiViTI calibration belt in both groups did not cross the diagonal bisector line. Therefore the predicted probability of the model was consistent with the actual probability which suggested that the calibration of the prediction model in both groups were perfect and prediction model had strong concordance performance. CONCLUSION: The individualized prediction model for patients with ureteral calculi can facilitate improved screening and early identification of patients having higher risk of urosepsis.


Sujet(s)
Modèles biologiques , Nomogrammes , Sepsie/épidémiologie , Sepsie/étiologie , Calculs urétéraux/complications , Calculs urétéraux/épidémiologie , Adulte , Femelle , Humains , Mâle , Adulte d'âge moyen , Valeur prédictive des tests , Études rétrospectives , Facteurs de risque , Sepsie/imagerie diagnostique , Sepsie/thérapie , Facteurs sexuels , Tomodensitométrie , Calculs urétéraux/imagerie diagnostique , Calculs urétéraux/thérapie
3.
Mol Cell Biochem ; 382(1-2): 283-91, 2013 Oct.
Article de Anglais | MEDLINE | ID: mdl-23820733

RÉSUMÉ

B cell-specific moloney murine leukemia virus integration site 1 (BMI1) is a transcriptional repressor of polycomb repressive complex 1, which is involved in the proliferation, senescence, migration, and tumorigenesis of cancer. Experimental researchers have convincingly linked BMI1 to tumorigenesis. However, there is no study about the issue on the role of BMI1 in the proliferation, apoptosis, and migration of bladder cancer. To address this question, we examined the expression of BMI1 in bladder cancer tissues and used siRNA to knockdown BMI1 expression in bladder cancer T24 cells. Then we tested the cell proliferation by CCK8 assay and soft agar colony formation assay, apoptosis by flow cytometry assay, and cell invasiveness by transwell migration assay. Our results revealed that BMI1 promoted proliferation, migration, invasion, and progression in bladder cancer. Over-expression of BMI1 was correlated with tumor clinic-pathological features. BMI1 siRNA effectively inhibited bladder cancer cell proliferation and migration in vitro, and it promoted bladder cancer invasion, maybe by causing epithelial-to-mesenchymal transition. Our findings suggested that BMI1 may represent a novel diagnostic marker and a therapeutic target for bladder cancer, and deserves further investigation.


Sujet(s)
Techniques de knock-down de gènes , Complexe répresseur Polycomb-1/métabolisme , Tumeurs de la vessie urinaire/métabolisme , Tumeurs de la vessie urinaire/anatomopathologie , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Apoptose/génétique , Marqueurs biologiques tumoraux/métabolisme , Cadhérines/métabolisme , Mouvement cellulaire/génétique , Prolifération cellulaire , Forme de la cellule , Inhibiteur p16 de kinase cycline-dépendante/métabolisme , Transition épithélio-mésenchymateuse/génétique , Femelle , Régulation de l'expression des gènes tumoraux , Humains , Immunohistochimie , Mâle , Adulte d'âge moyen , Invasion tumorale , Test clonogénique de cellules souches tumorales , Protéine p14(ARF) suppresseur de tumeur/métabolisme , Protéine-1 apparentée à Twist/métabolisme , Vessie urinaire/métabolisme , Vessie urinaire/anatomopathologie , Tumeurs de la vessie urinaire/génétique , Vimentine/métabolisme
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE